Endocrine Pharmacology Practice Questions

Q: Which type of insulin is indicated in diabetic ketoacidosis?

Soluble insulin intravenously infusion. **Explanation:** **1. Why Soluble Insulin Intravenously is Correct:** Diabetic Ketoacidosis (DKA) is a medical emergency characterized by severe dehydration, acidosis, and hyperglycemia [4]. **Soluble (Regular) insulin** is the drug of choice because it is the only form that can be administered intravenously [3]. The IV route is preferred in DKA for two reasons: * **Rapid Onset:** It provides an immediate effect to suppress lipolysis and ketogenesis. * **Titratability:** It has a short half-life (approx. 5–10 minutes) when given IV, allowing clinicians to adjust the infusion rate precisely based on hourly blood glucose monitoring [1]. **2. Why Other Options are Incorrect:** * **Lente and Protamine Zinc Insulin (Options A & C):** These are intermediate and long-acting "cloudy" insulins. They contain particles (zinc or protamine) that delay absorption. They are strictly contraindicated for IV use as they can cause embolic phenomena and have a delayed onset, making them useless in an acute crisis. * **Subcutaneous Route (Options A & B):** In DKA, patients often suffer from peripheral circulatory collapse (shock) and dehydration [4]. Subcutaneous absorption becomes erratic and unpredictable in such states. Therefore, the IV route is mandatory until the patient is stable [3]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Standard Protocol:** Low-dose IV insulin infusion (0.1 units/kg/hr) is the current standard of care [3]. * **The "Switch":** Transition to subcutaneous insulin only when the anion gap has closed and the patient is able to eat. * **Potassium Warning:** Insulin shifts potassium into cells. Always monitor K+ levels; if K+ is <3.3 mEq/L, delay insulin until potassium is replaced to avoid fatal arrhythmias [3][4]. * **Drug of Choice for Pregnancy:** Insulin remains the preferred agent for Gestational Diabetes Mellitus (GDM) [2].

Q: Which of the following drugs is a somatostatin analog?

Octreotide. No explanation text provided. **Explanation:** **1. Why Octreotide is correct:** **Octreotide** is a synthetic octapeptide analog of **somatostatin** (Growth Hormone Inhibiting Hormone) [1]. While natural somatostatin has a very short half-life (approx. 2 minutes), octreotide is much more potent and has a longer half-life (approx. 1.5 hours), making it clinically useful [1]. It acts by binding to somatostatin receptors (SSTR-2 and SSTR-5), leading to the inhibition of growth hormone (GH), glucagon, insulin, and various gastrointestinal hormones [2][3]. **2. Why the other options are incorrect:** * **Abarelix:** This is a **GnRH receptor antagonist** [5]. It is primarily used in the management of advanced prostate cancer to rapidly suppress testosterone levels without the initial "flare" seen with agonists [5]. * **Goserelin & Nafarelin:** These are **GnRH (Gonadotropin-Releasing Hormone) agonists**. While they initially stimulate FSH and LH, continuous administration leads to the downregulation of GnRH receptors, resulting in medical castration. They are used for endometriosis, precocious puberty, and prostate cancer. **3. High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Uses of Octreotide:** Acromegaly, secretory diarrheas (Carcinoid syndrome, VIPoma), and acute management of bleeding esophageal varices (by reducing splanchnic blood flow) [3][4]. * **Side Effects:** Biliary sludge and **gallstones** (due to inhibition of cholecystokinin and gallbladder contractility), steatorrhea, and nausea [3][4]. * **Other Analogs:** Lanreotide and Pasireotide (used specifically for Cushing’s disease) [2]. * **Mnemonic:** Remember **"S-O-L"** for Somatostatin analogs: **S**omatostatin, **O**ctreotide, **L**anreotide.

Q: Which of the following is NOT a mode of action of sulfonamides?

Decreasing glucose absorption from the gut.. **Explanation:** Sulfonylureas (often referred to in this context as sulfonamide derivatives) are insulin secretagogues used in Type 2 Diabetes Mellitus. Their primary mechanism involves stimulating the pancreas, but they also possess significant extrapancreatic effects. **Why Option D is Correct:** **Decreasing glucose absorption from the gut** is the mechanism of action of **Alpha-glucosidase inhibitors** (e.g., Acarbose, Miglitol) and, to a lesser extent, Biguanides (Metformin). Sulfonylureas have no pharmacological effect on intestinal glucose transport or carbohydrate digestion. **Analysis of Incorrect Options:** * **Option A:** This is the **primary pancreatic action**. Sulfonylureas bind to the SUR1 subunit of ATP-sensitive K⁺ channels on beta-cell membranes, causing channel closure, depolarization, calcium influx, and subsequent insulin release. * **Option B:** This is an **extrapancreatic action**. Sulfonylureas reduce hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis, thereby improving fasting plasma glucose. * **Option C:** Sulfonylureas increase **peripheral insulin sensitivity** by enhancing post-receptor signaling and increasing the number/sensitivity of insulin receptors on target tissues like muscle and fat. **High-Yield NEET-PG Pearls:** * **Generations:** First-gen (Tolbutamide - shortest acting) vs. Second-gen (Glimepiride - most potent). * **Side Effects:** Hypoglycemia (most common) and weight gain. * **Disulfiram-like reaction:** Classically associated with **Chlorpropamide**. * **Safety in Renal Failure:** **Gliquidone** is primarily excreted in bile, making it safer in renal impairment. * **K-ATP Channels:** These drugs also affect cardiac K-ATP channels; however, **Glimepiride** is considered more "pancreato-selective."

Q: Prolonged use of steroids may cause which of the following?

Decrease in bone matrix protein. ### Explanation **Correct Answer: A. Decrease in bone matrix protein** Prolonged use of glucocorticoids leads to **Glucocorticoid-Induced Osteoporosis (GIOP)** through several mechanisms. Steroids inhibit **osteoblasts** (bone-forming cells) and stimulate **osteoclasts** (bone-resorbing cells). Crucially, they decrease the synthesis of **Type I collagen** and other bone matrix proteins, leading to a reduction in the organic matrix (osteoid). Additionally, steroids decrease intestinal calcium absorption and increase renal calcium excretion, further weakening the bone. **Why the other options are incorrect:** * **B. Hypoglycemia:** Steroids are "diabetogenic." They stimulate gluconeogenesis and decrease peripheral glucose uptake, leading to **hyperglycemia**, not hypoglycemia. * **C. Hypotension:** Steroids have mineralocorticoid activity (causing sodium and water retention) and sensitize blood vessels to catecholamines. This typically results in **hypertension**. * **D. Early healing of wound:** Steroids **delay wound healing** by inhibiting fibroblast proliferation, reducing collagen synthesis, and suppressing the inflammatory response necessary for tissue repair. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site of steroid-induced fracture:** Vertebrae (followed by the femoral neck). * **Avascular Necrosis (AVN):** A serious complication of long-term steroid use, most commonly affecting the **head of the femur**. * **Prophylaxis:** Patients on long-term steroids should be started on **Calcium, Vitamin D, and Bisphosphonates** (the drug of choice for GIOP). * **Ocular side effects:** Steroids can cause **posterior subcapsular cataracts** and **glaucoma** (due to increased intraocular pressure).

Q: Which of the following conditions is a primary indication for the use of prostaglandins?

Missed abortion. **Explanation:** Prostaglandins (PGs) are potent stimulators of uterine smooth muscle contraction and are essential in obstetric practice for cervical ripening and uterine evacuation. **Why Missed Abortion is the Primary Indication:** In a **missed abortion**, the products of conception are retained despite fetal demise. Prostaglandins, specifically **Misoprostol (PGE1)**, are the drug of choice for medical management. They act by softening and dilating the cervix (cervical ripening) and inducing myometrial contractions to expel the retained tissue, avoiding the need for invasive surgical evacuation in many cases. **Analysis of Incorrect Options:** * **Second-trimester abortion:** While PGs (like Carboprost or Misoprostol) are used, they are often part of a combined regimen with Mifepristone. In the context of "primary" pharmacological management of a non-viable pregnancy, missed abortion is the classic indication. * **Ectopic pregnancy:** This is a **contraindication** for prostaglandin use. The primary medical management for an unruptured ectopic pregnancy is **Methotrexate** (a folate antagonist). * **Postpartum hemorrhage (PPH):** While **Carboprost (PGF2α)** and Misoprostol are used in PPH, they are typically **second-line** agents. **Oxytocin** remains the primary drug of choice for both the prevention and initial treatment of PPH. **High-Yield NEET-PG Pearls:** * **Misoprostol (PGE1):** Orally active, stable at room temperature; used for missed abortion and NSAID-induced peptic ulcers. * **Dinoprostone (PGE2):** Most commonly used for induction of labor (cervical ripening). * **Carboprost (15-methyl PGF2α):** Used for refractory PPH; contraindicated in **Asthma** due to bronchoconstriction. * **Gemeprost (PGE1 analog):** Specifically used for second-trimester abortions via vaginal suppository.

Q: Which is the most common adverse drug reaction of acarbose?

Flatulence. **Acarbose** is an **$\alpha$-glucosidase inhibitor** used in the management of Type 2 Diabetes Mellitus. Its mechanism involves inhibiting the enzyme $\alpha$-glucosidase at the brush border of the small intestine, which delays the digestion and absorption of complex carbohydrates (starch and sucrose) [1]. **Why Flatulence is the correct answer:** Because carbohydrate absorption is delayed, undigested carbohydrates reach the **colon**. Here, they undergo bacterial fermentation, leading to the production of gases (CO₂, H₂, and methane). This results in the most common side effects: **flatulence (seen in >70% of patients)**, abdominal bloating, and osmotic diarrhea [1]. **Analysis of Incorrect Options:** * **B. Hypoglycemia:** Acarbose does not stimulate insulin secretion (it is euglycemic). Therefore, it does not cause hypoglycemia when used as monotherapy [2]. * **C. Periodic Hyperglycemia:** Acarbose specifically targets **post-prandial hyperglycemia** by slowing glucose absorption; it does not cause rebound or periodic hyperglycemia. * **D. Weight gain:** Unlike sulfonylureas or insulin, acarbose is **weight-neutral** or may even cause modest weight loss, making it a preferred choice in obese diabetic patients. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment of Hypoglycemia:** If a patient on acarbose develops hypoglycemia (due to concurrent use of insulin or sulfonylureas), they must be treated with **pure glucose (dextrose)**, not sucrose (cane sugar), because acarbose prevents the breakdown of sucrose into glucose [2]. * **Contraindication:** It should be avoided in patients with **Inflammatory Bowel Disease (IBD)** or chronic intestinal disorders due to gas production.

Q: Insulin release due to closure of K+ channels is seen with which of the following drugs?

Nateglinde. **Explanation:** The correct answer is **Nateglinide**. **Mechanism of Action (Correct Option):** Nateglinide belongs to the **Meglitinide** (Glinide) class of oral hypoglycemics. Like Sulfonylureas, Meglitinides act as **insulin secretagogues**. They bind to a specific site on the **ATP-sensitive K+ channel (SUR1 subunit)** on the pancreatic beta-cell membrane. This binding causes the closure of K+ channels, leading to cell depolarization, opening of voltage-gated Ca2+ channels, and subsequent exocytosis of insulin. While they share the same mechanism as Sulfonylureas, Meglitinides have a quicker onset and shorter duration of action, making them ideal for controlling **post-prandial hyperglycemia**. **Analysis of Incorrect Options:** * **B. Acarbose:** An **alpha-glucosidase inhibitor** that acts in the intestinal brush border to delay the digestion and absorption of carbohydrates. It does not affect insulin secretion directly. * **C. Exenatide:** A **GLP-1 receptor agonist** (Incretin mimetic). It stimulates insulin release in a glucose-dependent manner via cAMP signaling, not by direct closure of K+ channels. * **D. Sitagliptin:** A **DPP-4 inhibitor** that prevents the breakdown of endogenous GLP-1 and GIP, thereby indirectly increasing glucose-dependent insulin secretion. **High-Yield Clinical Pearls for NEET-PG:** * **K+ channel blockers:** Sulfonylureas (e.g., Glimepiride) and Meglitinides (Repaglinide, Nateglinide). * **K+ channel openers:** Diazoxide and Minoxidil (can cause hypoglycemia inhibition/hyperglycemia). * **Nateglinide vs. Repaglinide:** Nateglinide is D-phenylalanine derivative; Repaglinide is a benzoic acid derivative. * **Safety:** Meglitinides are safer in patients with sulfur allergies (unlike Sulfonylureas) and carry a lower risk of prolonged hypoglycemia.

Q: Which one of the following oral hypoglycemic agents is not an insulin secretagogue?

Rosiglitazone. **Explanation:** The classification of oral hypoglycemic agents (OHAs) is based on their mechanism of action. **Insulin secretagogues** are drugs that stimulate the pancreas to release insulin, whereas **insulin sensitizers** improve the body's response to existing insulin. **Why Rosiglitazone is the correct answer:** Rosiglitazone belongs to the **Thiazolidinedione (TZD)** class. It acts as an **insulin sensitizer** rather than a secretagogue. Its primary mechanism involves activating the **PPAR-γ (Peroxisome Proliferator-Activated Receptor gamma)** receptors in adipose tissue, muscle, and liver. This leads to increased transcription of genes involved in glucose uptake (like GLUT-4) and lipid metabolism, thereby reducing insulin resistance. It does not directly stimulate pancreatic beta cells to release insulin. **Analysis of incorrect options:** * **Gliclazide & Glimepiride (Options A & B):** These are **Sulfonylureas** (2nd and 3rd generation respectively). They act by closing the ATP-sensitive K+ channels on the pancreatic beta-cell membrane, leading to depolarization, calcium influx, and subsequent insulin secretion. * **Repaglinide (Option C):** This is a **Meglitinide** analogue. Like sulfonylureas, it is a secretagogue that closes K+ channels, though it binds to a different site and has a shorter duration of action (used for postprandial glucose control). **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects of TZDs:** Weight gain, edema, and increased risk of congestive heart failure (due to fluid retention). Rosiglitazone specifically has been linked to increased cardiovascular risk. * **Secretagogues and Hypoglycemia:** Because they stimulate insulin release regardless of blood glucose levels, Sulfonylureas carry a high risk of hypoglycemia. * **Drug of Choice:** Metformin (a Biguanide) is also an insulin sensitizer (via AMPK activation) and is the first-line treatment for Type 2 Diabetes.

Q: What is an important difference between leuprolide and ganirelix regarding their effect on gonadotropin secretion?

Ganirelix immediately reduces gonadotropin secretion.. ### Explanation The key difference between these two drugs lies in their mechanism of action at the GnRH receptor. **1. Why Option B is Correct:** * **Ganirelix** is a **GnRH Receptor Antagonist**. It works by competitive blockade of the GnRH receptors in the anterior pituitary. This results in an **immediate** and direct inhibition of LH and FSH secretion. * **Leuprolide**, conversely, is a **GnRH Receptor Agonist**. When given continuously, it initially stimulates the receptors (causing a "flare"), and only after 1–2 weeks does it cause downregulation and desensitization of the receptors, leading to a decrease in gonadotropins. **2. Why the Other Options are Incorrect:** * **Option A:** Both leuprolide and ganirelix are peptides; they are degraded by GI enzymes and must be administered **parenterally** (SC/IM). * **Option C:** **Pulsatile** administration is a characteristic of native GnRH (or Gonadorelin) used to *treat* infertility by stimulating FSH/LH. Ganirelix is used to *suppress* the LH surge. * **Option D:** This describes the "flare effect" seen with **Leuprolide** (GnRH agonist). Ganirelix, being an antagonist, does not cause an initial stimulation. ### NEET-PG High-Yield Pearls: * **Clinical Use:** Ganirelix and Cetrorelix are primarily used in **Controlled Ovarian Hyperstimulation (IVF)** to prevent a premature LH surge. * **Advantage of Antagonists:** Unlike agonists (Leuprolide), GnRH antagonists do not require co-administration of anti-androgens (like Flutamide) because there is no initial testosterone surge/flare. * **Degarelix:** Another GnRH antagonist used specifically for advanced prostate cancer to achieve rapid testosterone suppression.

Question 1

Which type of insulin is indicated in diabetic ketoacidosis?

Accepted Answer

Soluble insulin intravenously infusion

Answer

Lente insulin subcutaneously

Answer

Soluble insulin subcutaneously

Answer

Protamine zinc insulin intramuscularly

Question 2

Which of the following drugs is a somatostatin analog?

Accepted Answer

Octreotide

Answer

Abarelix

Answer

Goserelin

Answer

Nafarelin

Question 3

Which of the following is NOT a mode of action of sulfonamides?

Accepted Answer

Decreasing glucose absorption from the gut.

Answer

Activating receptors on beta cells of the pancreas to release insulin.

Answer

Inhibiting gluconeogenesis in the liver.

Answer

Enhancing insulin-mediated post-receptor enzyme reactions.

Question 4

Prolonged use of steroids may cause which of the following?

Accepted Answer

Decrease in bone matrix protein

Answer

Hypoglycemia

Answer

Hypotension

Answer

Early healing of wound

Question 5

Which of the following conditions is a primary indication for the use of prostaglandins?

Accepted Answer

Missed abortion

Answer

Second-trimester abortion

Answer

Ectopic pregnancy

Answer

Postpartum hemorrhage (PPH)

Question 6

Which is the most common adverse drug reaction of acarbose?

Accepted Answer

Flatulence

Answer

Hypoglycemia

Answer

Periodic Hyperglycemia

Answer

Weight gain

Question 7

What is the most common side effect seen with bisphosphonates?

Accepted Answer

Erosive esophagitis

Answer

Cholelithiasis

Answer

Constipation

Answer

Osteonecrosis

Question 8

Insulin release due to closure of K+ channels is seen with which of the following drugs?

Accepted Answer

Nateglinde

Answer

Acarbose

Answer

Exenatide

Answer

Sitagliptin

Question 9

Which one of the following oral hypoglycemic agents is not an insulin secretagogue?

Accepted Answer

Rosiglitazone

Answer

Gliclazide

Answer

Glimiperide

Answer

Repaglinide

Question 10

What is an important difference between leuprolide and ganirelix regarding their effect on gonadotropin secretion?

Accepted Answer

Ganirelix immediately reduces gonadotropin secretion.

Answer

Ganirelix can be given orally.

Answer

Ganirelix must be given in a pulsatile fashion.

Answer

Ganirelix initially stimulates the release of LH and FSH.

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?